AAAOM
ACTRN12608000424303
Government body, National Health and Medical Research Council
Andre Wattiaux
The primary aim of this study is to evaluate whether azithromycin compared with no treatment results in a reduction in the proportion of children with signs of persistent disease 14 days after starting treatment.
1. Informed consent obtained and signed 2. All Aboriginal children aged 6 months and 30 months of age on the date of randomisation who are resident in participating communities will be eligible to be screened for asymptomatic acute otitis media without perforation. 3. The following inclusion criteria for the randomized controlled trial (RCT) will be applied to children diagnosed with asymptomatic acute otitis media: a.) A bulging tympanic membrane. b.) No associated symptoms at the time of diagn .... Read more
1. Acute otitis media with ear pain or fever 2. Acute otitis media with recent onset of perforation and discharge (within 7 days) 3. Chronic suppurative otitis media 4. Previously been randomised into this study 5. Have received antibiotics in the previous 7 days (not including topical antibiotics) 6. A more severe illness requiring antibiotics 7. Azithromycin allergy 8. Immunodeficiency
No
Sample Size 300
Min. age 6 Months
Max. age 30 Months
Sex Both males and females
Condition category Acute otitis media without perforation
Condition code Ear
Intervention code Treatment: Drugs
Two doses of 30mg/kg of azithromycin or the placebo will be adminstered a week a apart on Day 0 and Day 7. The mode of administration of the drug will be oral suspension.
Control group Placebo
The placebo is custom made to smell, taste and imitate azithromycin.
Outcome: Clinical failure (All): Proportion of children with bulging or middle ear discharge at 14 days or withdrawn due to complications or side effects. All children who are lost to follow up are considered clinical failures.Timepoint: 14 days after commencement of intervention
To assist secondary data users in understanding the real-world impact of health and medical research data sharing, the Australian Research Data Commons (ARDC) has created an online guide that outlines a theoretical framework for four key data reuse scenarios. This practical guide was extracted from research papers, and consultation with stakeholders and the research community.
With Health Data Australia, researchers can explore descriptions of data from our publishing partners, identify relevant datasets, and request access. These requests will then be forwarded to the data owner for review.
To start requesting data, simply login with your AAF account.